He Lilin, Shen Yongxiang
Department of Oncology, The First People's Hospital of Tianmen City, Tianmen, Hubei Province, People's Republic of China.
Onco Targets Ther. 2017 Jan 6;10:227-238. doi: 10.2147/OTT.S121472. eCollection 2017.
Previous studies have found that many gene variations can be detected in both breast cancer and ovarian cancer, which is beneficial for the elaboration of the molecular origin of breast and ovarian cancer. Furthermore, many studies have explored the association of methylenetetrahydrofolate reductase () polymorphism with the risk of breast cancer and/or ovarian cancer; however, the results remained inconclusive. Therefore, this study conducted a systematic review and meta-analysis to evaluate the association between polymorphism and the risk of breast and ovarian cancer.
A total of 50 studies with 19,260 cases and 26,364 controls including 39 studies for breast cancer and 8 studies for ovarian cancer were identified on searching through PubMed, Embase, Web of Science, China National Knowledge Infrastructure, WanFang, and Database of Chinese Scientific and Technical Periodicals (VIP). Allele model, dominant model, recessive model, homozygous model, and co-dominant model were applied to evaluate the association of polymorphism with breast cancer and/or ovarian cancer risk. Moreover, the odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of the association between polymorphism and breast and ovarian cancer risk.
A significantly increased breast cancer risk was observed in the overall analysis (for C vs T, OR =1.19, CI: 1.12-1.28, <0.05; for CC vs TT, OR =1.20, CI: 1.10-1.23, <0.05; for (CT+CC) vs TT, OR =1.19, CI: 1.11-1.27, <0.05; for CC vs (CT+TT), OR =1.19, CI: 1.79-1.95, <0.05), while no significantly increased ovarian cancer risk was detected. In the subgroup analysis based on ethnicity, a significant association of breast cancer and/or ovarian cancer risk with polymorphism was observed in Asians. Interestingly, there was no significant association between polymorphism and ovarian cancer risk in Caucasians, whereas a significantly increased risk of breast cancer was found in Caucasians.
This meta-analysis demonstrates that polymorphism may be a risk factor for breast and ovarian cancer, especially in Asians.
既往研究发现,在乳腺癌和卵巢癌中均可检测到许多基因变异,这有助于阐明乳腺癌和卵巢癌的分子起源。此外,许多研究探讨了亚甲基四氢叶酸还原酶(MTHFR)基因多态性与乳腺癌和/或卵巢癌风险的关联;然而,结果仍不明确。因此,本研究进行了一项系统评价和荟萃分析,以评估MTHFR基因多态性与乳腺癌和卵巢癌风险之间的关联。
通过检索PubMed、Embase、Web of Science、中国知网、万方和维普数据库,共纳入50项研究,包括19260例病例和26364例对照,其中39项研究涉及乳腺癌,8项研究涉及卵巢癌。采用等位基因模型、显性模型、隐性模型、纯合子模型和共显性模型评估MTHFR基因多态性与乳腺癌和/或卵巢癌风险的关联。此外,计算比值比(OR)及95%置信区间(CI),以评估MTHFR基因多态性与乳腺癌和卵巢癌风险之间关联的强度。
在总体分析中观察到乳腺癌风险显著增加(C与T相比,OR = 1.19,CI:1.12 - 1.28,P < 0.05;CC与TT相比,OR = 1.20,CI:1.10 - 1.23,P < 0.05;(CT + CC)与TT相比,OR = 1.19,CI:1.11 - 1.27,P < 0.05;CC与(CT + TT)相比,OR = 1.19,CI:1.79 - 1.95,P < 0.05),而未检测到卵巢癌风险显著增加。在基于种族的亚组分析中,在亚洲人中观察到MTHFR基因多态性与乳腺癌和/或卵巢癌风险存在显著关联。有趣的是,在白种人中,MTHFR基因多态性与卵巢癌风险无显著关联,而在白种人中发现乳腺癌风险显著增加。
本荟萃分析表明,MTHFR基因多态性可能是乳腺癌和卵巢癌的一个风险因素,尤其是在亚洲人中。